SpringWorks Therapeutics Inc
(NAS:SWTX)
$
36.12
-0.08 (-0.22%)
Market Cap: 2.68 Bil
Enterprise Value: 2.25 Bil
PE Ratio: 0
PB Ratio: 4.71
GF Score: 40/100 - Q1 2024 SpringWorks Therapeutics Inc Earnings Call TranscriptMay 02, 2024$43.35 (-7.45%)Earnings
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- SpringWorks Therapeutics to Discuss The ReNeu Topline Data TranscriptNov 16, 2023
- SpringWorks Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- SpringWorks Therapeutics Inc at TD Cowen Oncology Innovation Summit (Virtual) TranscriptMay 31, 2023
- SpringWorks Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- SpringWorks Therapeutics Inc at Cowen Health Care Conference TranscriptMar 07, 2023
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- SpringWorks Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- SpringWorks Therapeutics Inc at H.C. Wainwright Precision Oncology Conference (Virtual) TranscriptNov 14, 2022
- SpringWorks Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- SpringWorks Therapeutics Inc R&D Day (Virtual) TranscriptJun 10, 2022
- SpringWorks Therapeutics Inc To Discuss The DeFi Trial Data Call TranscriptMay 24, 2022
- SpringWorks Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- SpringWorks Therapeutics Inc and the ReNeu Trial for NF1-Related Plexiform Neurofibromas TranscriptJul 15, 2021
- SpringWorks Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- SpringWorks Therapeutics to Discuss the Reneu Trial Data and Program Update Call TranscriptFeb 25, 2021
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- SpringWorks Therapeutics Inc Clinical Trials TranscriptOct 13, 2020
SpringWorks Therapeutics Inc at H.C. Wainwright Precision Oncology Conference (Virtual) Transcript
Nov 14, 2022 / 03:30PM GMT
Release Date Price:
$26.18
(+4.80%)
Robert Burns
H.C. Wainwright & Co., LLC - Analyst
Welcome to our next fireside chat with SpringWorks Therapeutics. I'm Robert Burns, Managing Director and Senior Biotech Analyst at H.C. Wainwright. And I'm joined today by Badreddin Edris, the Chief Operating Officer of SpringWorks. Badreddin, thank you for joining us today.
Badreddin Edris
SpringWorks Therapeutics, Inc. - COO
Thanks for having us, Rob. We appreciate the opportunity to be here.
Questions & Answers
Robert Burns
H.C. Wainwright & Co., LLC - Analyst
So I will just dive in. And so for those who may be unfamiliar with SpringWorks, can you provide a brief overview of the company as well as its pipeline?
Badreddin Edris
SpringWorks Therapeutics, Inc. - COO
Yes, absolutely. Happy to do so and happy to have the opportunity to share the story at a high level during what continues to be a pivotal year as we come to the end of it and look forward to what comes next. So for those tuning in who
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)